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Background: Cardiomyopathy (CM) is an inevitable consequence of Duchenne muscular dystrophy (DMD). Suggested treatments include 
angiotensin-converting enzyme inhibitors (ACEI) and/or beta-blockers (BB), but few large series have been reported. We present 65 DMD patients 
with CM treated with ACEI or ACEI+BB, including their natural history and responses to therapy.
Methods: Serial echocardiograms were performed and reported for natural history analysis prior to initiation of therapy when available. Adequate 
ejection fractions (EF) were obtained in 45 patients at initiation of therapy (EF<55%). Twenty patients were excluded due to pre-existing ACEI therapy 
(n=11), inadequate follow-up (n=8), or inadequate echocardiogram (n=1). ACEI dosage adjustments were made if a continued decrease in EF was 
noted. BB therapy was initiated when average heart rate on Holter exceeded 100 beats/min. Data were analyzed using paired t-test and linear 
regression.
Results: Natural history data prior to ACEI (n=24) demonstrated decreased EF over time. (r2=0.22). At initiation of ACEI therapy, the mean age was 
14.7 ± 4.4 years and mean EF was 44.3 ± 8.3%. BB therapy was used in 25/45 patients. Mean age for ACEI+BB group was 16.1 ± 3.9 years. Both 
groups demonstrated significant improvement (p≤0.0001 for ACEI, and p<0.001 for ACEI+BB) compared to natural history. No significant difference 
was noted between treatment groups.
Conclusions: In conclusion, patients with DMD demonstrated gradual decline in myocardial function. Treatment with ACEI or ACEI+BB resulted in 
significant improvement compared to the natural history. There was no significant difference in EF improvement between treatment groups. Treatment 
with ACEI or ACEI+BB can delay progression of CM.
